Interstitial Lung Anomaly and Lung Cancer

The prevalence of immune checkpoint inhibitor-related pneumonitis has been reported to be 4.1% amongst lung cancer patients in anti-programmed cell death protein 1 inhibitor trials. Cytotoxic chemotherapy and targeted drug therapy are major treatment options for patients with lung cancer, but it is well known that both of these therapies can cause exacerbation of interstitial lung disease or drug- related pneumonitis. The Fleischer Society position paper also recommended that active monitoring for symptoms, physiological alterations, and imaging-depicted progression of drug-related pneumonia should be considered.